Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lupi-Herrera, E
Right arrow Articles by Sobrino, A
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lupi-Herrera, E
Right arrow Articles by Sobrino, A

Chest, Vol 79, 292-296, Copyright © 1981 by American College of Chest Physicians

ARTICLES

The role of isoproterenol in pulmonary artery hypertension of unknown etiology (primary): short- and long-term evaluation

E Lupi-Herrera, D Bialostozky and A Sobrino

The experience derived from the administration of isoproterenol in six patients with pulmonary hypertension of unknown etiology (PAH-UE) is presented. The diagnosis was made after exclusion of other known diseases capable of producing hypertension in the pulmonary circuit. Catheterization was performed, and basal cardiopulmonary parameters, mean pulmonary artery pressure (PAP), pulmonary arteriolar resistance (PAR), cardiac index (CI), alveolar-arterial oxygen tension difference P(A-a)O2, and PaO2 were investigated. The effect of infusing 3 micrograms/min of isoproterenol into the pulmonary artery was studied in five cases. Isoproterenol was given sublingually to one patient who had previously received it intravenously; in another case it was given only sublingually. Significant P values (P less than .05) as a group were obtained, in relation to heart rate, CI, PAR, and mean PAP after isoproterenol. A favorable effect on the heart and lungs was seen in two cases, maintained for three years with sublingual isoproterenol with a favorable cardiorespiratory effect. Use of isoproterenol in PAH- UE is justified at present in those cases with a favorable cardiopulmonary response while no specific therapy is available.


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
A. Gomez, D. Bialostozky, A. Zajarias, E. Santos, A. Palomar, M. L. Martinez, and J. Sandoval
Right ventricular ischemia in patients with primary pulmonary hypertension
J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1137 - 1142.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by the American College of Chest Physicians.